Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bronchodilator Agents Clear all
Terminated Phase 3 Interventional Results available

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

NCT01218009
View directory record Official record
Conditions
Asthma
Interventions
Placebo Spiromax, Albuterol Spiromax
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

NCT03673670
View directory record Official record
Conditions
COPD
Interventions
RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat)
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Winter Park, Florida • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of the Aeroneb in Acute Severe Asthma

NCT03029156
View directory record Official record
Conditions
Asthma Exacerbation
Interventions
Aeroneb nebulizer, Small volume jet nebulizer
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

NCT01328444
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125, GSK 573719 62.5, GW642444 25, Plb
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Lebanon, New Hampshire • Albany, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

NCT00749411
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, GSK233705/GW642444
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 9, 2026, 5:52 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

NCT05095116
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011 3 mg HS
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years and older
U.S. locations
35
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Camarillo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 9, 2026, 5:52 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

NCT00461812
View directory record Official record
Conditions
Asthma
Interventions
Mometasone, Advair
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis

NCT01488448
View directory record Official record
Conditions
Bronchiolitis
Interventions
3% sodium chloride, 0.9% sodium chloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Up to 12 Months
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

NCT05634746
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
59
States / cities
Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 9, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

NCT00085774
View directory record Official record
Conditions
Exercise-induced Bronchospasm
Interventions
albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

PF-04191834 Single Dose Bronchodilatory Study In Asthma.

NCT00723021
View directory record Official record
Conditions
Asthma
Interventions
PF-04191834, zileuton, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • North Dartmouth, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 9, 2026, 5:52 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01154127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Sep 9, 2026, 5:52 PM EDT
Not listed Phase 1 Interventional

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

NCT01355991
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008423
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
62
States / cities
Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

NCT01323660
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125, GSK573719 62.5, GW642444 25, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older · Male only
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jasper, Alabama • Torrance, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

NCT00413205
View directory record Official record
Conditions
Emphysema
Interventions
Placebo, RAR Gamma
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
44 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 9, 2026, 5:52 PM EDT
Completed No phase listed Observational Results available

Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy

NCT00791518
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
No intervention
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,084 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
57
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 9, 2026, 5:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

NCT03137784
View directory record Official record
Conditions
Asthma
Interventions
NVA237 (glycopyrronium bromide), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 9, 2026, 5:52 PM EDT